Home Halogens 2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid

2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid

CAS No.:
53882-12-5
Catalog Number:
AG003AEL
Molecular Formula:
C11H6ClN3O6
Molecular Weight:
311.6348
Pack Size
Purity
Availability
Location
Price(USD)
Quantity
  
5mg
99%
1 week
United States
$126
- +
10mg
99%
1 week
United States
$154
- +
25mg
≥95%
1 week
United States
$166
- +
50mg
99%
1 week
United States
$251
- +
100mg
99%
1 week
United States
$390
- +
200mg
99%
1 week
United States
$640
- +
Product Description
Catalog Number:
AG003AEL
Chemical Name:
2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid
CAS Number:
53882-12-5
Molecular Formula:
C11H6ClN3O6
Molecular Weight:
311.6348
MDL Number:
MFCD00864803
IUPAC Name:
2-[2-chloro-5-cyano-3-(oxaloamino)anilino]-2-oxoacetic acid
InChI:
InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)
InChI Key:
RVGLGHVJXCETIO-UHFFFAOYSA-N
SMILES:
N#Cc1cc(NC(=O)C(=O)O)c(c(c1)NC(=O)C(=O)O)Cl
UNII:
SPU695OD73
Properties
Complexity:
489  
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
310.995g/mol
Formal Charge:
0
Heavy Atom Count:
21  
Hydrogen Bond Acceptor Count:
7  
Hydrogen Bond Donor Count:
4  
Isotope Atom Count:
0
Molecular Weight:
311.634g/mol
Monoisotopic Mass:
310.995g/mol
Rotatable Bond Count:
4  
Topological Polar Surface Area:
157A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
0.5  
Literature
Title Journal
GPR35 mediates lodoxamide-induced migration inhibitory response but not CXCL17-induced migration stimulatory response in THP-1 cells; is GPR35 a receptor for CXCL17? British journal of pharmacology 20180101
Ocular medicines in children: the regulatory situation related to clinical research. BMC pediatrics 20120101
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). PLoS computational biology 20111201
Involvement of nitric oxide pathways in neurogenic pulmonary edema induced by vagotomy. Clinics (Sao Paulo, Brazil) 20110601
Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis. Gastroenterology 20110501
Safety and efficacy of lodoxamide in vernal keratoconjunctivitis. JPMA. The Journal of the Pakistan Medical Association 20110301
Multiple endpoint analysis of BAC-preserved and unpreserved antiallergic eye drops on a 3D-reconstituted corneal epithelial model. Molecular vision 20110101
Updates in the treatment of ocular allergies. Journal of asthma and allergy 20100101
Cromoglycate drugs suppress eicosanoid generation in U937 cells by promoting the release of Anx-A1. Biochemical pharmacology 20090615
Immediate hypersensitivity elicits renin release from cardiac mast cells. International archives of allergy and immunology 20080101
Secondary bacterial keratitis associated with shield ulcer caused by vernal conjunctivitis. Cornea 20060901
Cardiac mast cell-derived renin promotes local angiotensin formation, norepinephrine release, and arrhythmias in ischemia/reperfusion. The Journal of clinical investigation 20060403
A clinicopathological analysis of the efficacy of lodoxamide 0.1% eye drops on the conjunctiva of patients with vernal keratoconjunctivitis seen at Guinness Eye Centre, Lagos University Teaching Hospital. The Nigerian postgraduate medical journal 20060301
Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 20050101
Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. The British journal of general practice : the journal of the Royal College of General Practitioners 20040601
Tear and serum eosinophil cationic protein levels in seasonal allergic conjunctivitis. European journal of ophthalmology 20031001
Effects of ketotifen 0.025% and lodoxamide 0.1% on eosinophil infiltration into the guinea pig conjunctiva in a model of allergic conjunctivitis. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics 20030401
[In vitro effects of antiallergic eyedrops on complement activation induced by particulate matter]. Journal francais d'ophtalmologie 20030401
Vernal keratoconjunctivitis in Thailand. Asian Pacific journal of allergy and immunology 20030301
Comparison of antiallergic drugs in an experimental model of ocular anaphylaxis. Ophthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde 20030101
[Evaluation of the efficacy and safety of lodoxamide in patients with allergic eye diseases]. Acta medica Croatica : casopis Hravatske akademije medicinskih znanosti 20020101
Comparison of lodoxamide 0.1% ophthalmic solution and levocabastine 0.05% ophthalmic suspension in vernal keratoconjunctivitis. European journal of ophthalmology 20010101
[Evaluation of efficacy and safety of sterile solution of lodoxamide in patients with ocular allergy]. Oftalmologia (Bucharest, Romania : 1990) 20010101
Lodoxamide as adjuvant therapy in patients with dry eye. Collegium antropologicum 20010101
Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology 20000701
Lodoxamide versus spaglumic acid: a comparative double-blind trial on patients suffering from seasonal allergic conjunctivitis induced by Parietaria pollen. Allergologia et immunopathologia 19970101
Lodoxamide in vernal keratoconjunctivitis. The Annals of pharmacotherapy 19960501
Properties